Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01769547
Title A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals
Indications

malignant pleural mesothelioma

Therapies

Dovitinib

Age Groups: adult
Covered Countries CAN


No variant requirements are available.